Healthcare Gainers: Health Insurance Innovations Inc (NASDAQ:HIIQ), Biostar Pharmaceuticals (NASDAQ:BSPM), Applied Genetic Technologies (NASDAQ:AGTC), Versartis Inc (NASDAQ:VSAR), Sorrento Therapeutics (NASDAQ:SRNE)

Research analysts at Dougherty & Co assumed coverage on shares of Health Insurance Innovations Inc (NASDAQ:HIIQ) in a report released on Friday, reports. The firm set a “buy” rating on the stock. Health Insurance Innovations Inc (NASDAQ:HIIQ) stock performance was 5.89% in last session and finished the day at $10.43. Traded volume was 30,114.00million shares in the last session and the average volume of the stock remained 49.03K shares. Health Insurance Innovations Inc (NASDAQ:HIIQ) insider ownership is 0.80%.

On March 10, 2014, Biostar Pharmaceuticals, Inc. (NASDAQ:BSPM) and certain institutional investors entered into a securities purchase agreement (the “Purchase Agreement”) in connection with an offering (“Offering”) pursuant to which the Company agreed to sell, and the investors agreed to purchase 1,650,000 shares of the Company’s common stock and warrants to purchase up to 660,000 shares of the Company’s common stock, for aggregate gross proceeds, before deducting fees to the placement agents and other estimated offering expenses payable by the Company, of approximately $4.1 million. Biostar Pharmaceuticals Inc (NASDAQ:BSPM) rose 5.26 percent to $1.40 Friday on volume of 41,668.00million shares. The intra-day range of the stock was $1.34 to $1.40. Biostar Pharmaceuticals Inc (NASDAQ:BSPM) has a market capitalization of $20.06million.

BMO Capital Markets boosted their price target on shares of Applied Genetic Technologies Corp (NASDAQ:AGTC) from $21.00 to $34.00 in a research note issued on Monday. The firm currently has an “outperform” rating on the stock. BMO Capital Markets’ target price points to a potential upside of 34.44% from the stock’s previous close. Applied Genetic Technologies Corp (NASDAQ:AGTC)’s stock on June 13, 2014 reported a increase of 6.26% to the closing price of $27.49. Its fifty two weeks range is $11.10 -$29.63. The total market capitalization recorded $387.00million. The overall volume in the last trading session was 56,787.00million shares. In its share capital, AGTC has 14.08million outstanding shares.

Biopharmaceutical company Versartis Inc. (NASDAQ:VSAR) has selected Comprehend Systems to help facilitate compilation of real-time study information and subject data. The market’s only cloud-based platform with the ability to easily access and analyze data from any clinical IT system Comprehend Clinical enables all users including clinical operations and medical affairs to have immediate access to critical site data for optimal trial management and safety review. On Friday, shares of Versartis Inc (NASDAQ:VSAR) advanced 6.65% to close the day at $34.00. Company monthly performance is recorded as 19.34%.

Sorrento Therapeutics, Inc. (NASDAQ:SRNE), a late-stage clinical oncology company developing new treatments for cancer and its associated pain, on 12 June 2014 announced that the underwriters of its previously announced underwritten public offering of 4,765,000 shares of its common stock have exercised in full their option to purchase an additional 714,750 shares of common stock from the Company at $5.25 per share to cover over-allotments, bringing total gross proceeds from this offering to approximately $28,768,000 before deducting underwriting discounts and commissions and other offering expenses payable by the Company. The offering of these additional shares is expected to close on or about June 16th, 2014, subject to customary closing conditions. Sorrento Therapeutics Inc (NASDAQ:SRNE) stock performance was 5.85% in last session and finished the day at $5.43. Traded volume was 130,318.00million shares in the last session and the average volume of the stock remained 178.38K shares. The beta of the stock remained 4.26. Sorrento Therapeutics Inc (NASDAQ:SRNE) insider ownership is 2.20%.